MetaCap

Actinium Pharmaceuticals Inc. (Delaware) (ATNM)

NYSE: ATNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.05-0.02 (-1.87%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ATNM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$33.01M
52-week range
0.735 – 1.72
Day range
1.00 – 1.10
Volume / Avg
280.66K / 193.83K
Beta
—

52-week range

$0.735$1.72

ATNM stock today

On Nov 20, ATNM ended the session at $1.05, shedding $0.02 (1.87%), versus the S&P 500's 3.70% decline. At this level, ATNM sits in the middle of its 52-week range of $0.735 to $1.72: 39.0% below the high, set on Dec 22, 2025 and 42.9% above the low. ATNM is down 22.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 21.1%.

Actinium Pharmaceuticals (Delaware) trades at 2.4x its trailing twelve-month earnings per share of $0.43.

Summary generated from market data by MetaCap's automated system. Methodology

About Actinium Pharmaceuticals (Delaware)

Company profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Headquarters
New York, NY
Employees
27

Financial highlights

Full financials

In fiscal 2025, Actinium Pharmaceuticals (Delaware) generated $90,000 in revenue. Actinium Pharmaceuticals (Delaware) reported a net loss of $33.9 million, compared with a loss of $38.2 million a year earlier. Operating margin was -40274.4%.

Actinium Pharmaceuticals (Delaware) annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$90.00K—$81.00K$1.03M$1.14M
Growth——-92.14%-9.97%—
Net income$-33.89M$-38.24M$-48.82M$-33.02M$-24.77M
EPS (diluted)$-1.09$-1.27$-1.83$-1.37$-1.20

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$3.60+242.86%

  • Strong buy 1
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.19 vs $-0.25
Surprise
+24.00%

ATNM news

All ATNM news

Actinium Pharmaceuticals (Delaware) peers

Health Care sector
ATNM peer companies
CompanyPrice% ChgMarket capCompare
VERUVeru Inc.1.94-8.06%$33.08Mvs ATNM
HYFTMindWalk Holdings Corp.0.6844-14.27%$32.56Mvs ATNM
GRDXGridAI Technologies Corp.3.16-8.41%$32.44Mvs ATNM
FLNAFilana Therapeutics Inc.0.6413+14.52%$32.26Mvs ATNM
CUECue Biopharma Inc.4.15-7.78%$34.69Mvs ATNM
GRCEGrace Therapeutics Inc.1.71-0.58%$35.97Mvs ATNM
SERSerina Therapeutics Inc.1.12-6.67%$29.76Mvs ATNM
NXTCNextCure Inc.6.45-4.87%$29.53Mvs ATNM

Indexes, lists and sector

Actinium Pharmaceuticals (Delaware) stock FAQ

What is Actinium Pharmaceuticals (Delaware)'s stock price today?

ATNM last traded at $1.05 as of Nov 20, 4:00 PM EST, down 1.87% on the day. Prices are delayed at least 15 minutes.

Does Actinium Pharmaceuticals (Delaware) pay a dividend?

No. Actinium Pharmaceuticals (Delaware) does not currently pay a regular cash dividend.

What is ATNM's P/E ratio?

ATNM trades at a trailing P/E ratio of 2.44.

Who is Actinium Pharmaceuticals (Delaware)'s CEO?

Mr. Sandesh C. Seth M.B.A., M.S. is the chief executive officer of Actinium Pharmaceuticals Inc. (Delaware), which has about 27 employees.

Has ATNM ever split its stock?

Yes. The most recent ATNM stock split was a 1-for-30 split on Aug 11, 2020.

What is the ATNM 52-week high?

The 52-week high for ATNM is $1.72 and the 52-week low is $0.735. The stock is currently 39.0% below its high.

Compare ATNM